Latest Breaking News On - Jeffreym dayno - Page 1 : comparemela.com

Harmony's Q1 Report Shows Growth in Sleep/Wake Portfolio

Harmony Biosciences Holdings Inc reported first-quarter results, showcasing progress in its sleep/wake portfolio.

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its ...

WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year

Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View - Harmony Biosciences (NASDAQ:HRMY)

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations.

Harmony Secures Rights to Develop Bioprojet's Orexin-2 Agonist

Harmony has entered into a licensing agreement to develop and commercialize TPM-1116, a selective oral orexin-2 receptor agonist.